Yıl: 2021 Cilt: 27 Sayı: 2 Sayfa Aralığı: 158 - 163 Metin Dili: İngilizce DOI: 10.4274/tnd.2021.89983 İndeks Tarihi: 19-01-2022

Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia

Öz:
Objective: To screen cognitive functions using the Montreal Cognitive Assessment (MoCA) test and to determine the most common central nervous system complications in adults with sickle cell anemia (SCA). Materials and Methods: One hundred adult patients with SCA and 82 healthy controls participated in this study. Controls were matched for age, sex, and education level. We reviewed the demographic information and laboratory values of all patients. The patients were questioned about common CNS complications including headache, ischemic or hemorrhagic stroke, epilepsy, and cerebral venous sinus thrombosis. The MoCA test was used to assess neurocognitive function in all participants. Results: Of the 100 patients with SCA, 38 patients had chronic or recurrent headaches, 10 had a history of depression, and four patients had a history of ischemic stroke. None of the patients had a history of epilepsy, hemorrhagic stroke or cerebral venous sinus thrombosis. The median MoCA score of the patients was significantly decreased compared with that of the control group (p<0.001). MoCA scores below 21 points were observed in 50% of the patients. The MoCA scores were negatively correlated with age but positively correlated with education level (r=-0.181 p=0.015, r=0.483, p<0.001 respectively). There was a significant correlation between a history of chronic or recurrent headaches and lower MoCA (p=0.003). Conclusion: Cognitive impairment was the most prevalent neurologic symptom in Turkish adult patients with SCA. The MoCA test may be a useful and easy screening test to evaluate and follow cognitive impairment. A history of first ischemic stroke during adulthood was observed in one patient. Two patients had severe neurologic sequela findings due to ischemic stroke.
Anahtar Kelime:

Türk Erişkin Orak Hücreli Anemi Hastalarında Montreal Bilişsel Değerlendirme Ölçeği ile Kognitif Bozukluğunun Taranması ve Nörolojik Komplikasyonların Değerlendirilmesi

Öz:
Amaç: Orak hücre anemili (OHA) erişkin hastaların Montreal Bilişsel Değerlendirme (MoCA) testi ile bilişsel işlevlerini değerlendirmek ve bu hastalarda sık karşılaşılan merkezi sinir sistemi komplikasyonlarınını belirlemektir. Gereç ve Yöntem: Çalışmaya 100 OHA tanılı erişkin hasta ve 82 sağlıklı kontrol grubu dahil edildi. Kontrol grubu ile hasta grup yaş, cinsiyet ve eğitim açısından eşleştirildi. Tüm hastaların demografik bilgileri ve laboratuvar değerleri kaydedildi. Hastalar kronik veya sık aralıklı baş ağrısı, iskemik veya hemorajik inme, epilepsi, serebral venöz sinüs trombozu gibi yaygın santral sinir sistemi komplikasyon öyküleri olup olmadığı açısından sorgulandı. Çalışmaya alınan tüm bireylerin bilişsel fonksiyonları MoCA testi ile değerlendirildi. Bulgular: Yüz OHA’lı hastanın 38’inde kronik veya tekrarlayan baş ağrısı, 10’ununda depresyon öyküsü, 4’ünde iskemik inme öyküsü vardı. Hiçbir hastada epilepsi, hemorajik inme ve serebral venöz sinüs trombozu öyküsü yoktu. Hastaların medyan MoCA skorları kontrol grubuna göre anlamlı olarak düşüktü (p<0,001). Hastaların %50’sinde 21 puanın altında MoCA skorları gözlendi. Hastaların MoCA total puanları yaş ile negatif, eğitim düzeyi ile pozitif korelasyon gösterdi (r=-0,181 p=0,015, r=0,483 p<0,001). Kronik veya tekrarlayan baş ağrısı öyküsü düşük MoCA skoru ile anlamlı derecede ilişkili idi (p=0,003). Sonuç: OHA’lı Türk erişkin hastalarda en sık görülen nörolojik semptom bilişsel bozukluktu. MoCA testi, OHA’lı hastalarda bilişsel bozukluğu değerlendirmek ve takip etmek için yararlı ve kolay bir tarama testi olabilir. Erişkinlik döneminde iskemik inme bir hastada gözlendi. İki hastada iskemik inme nedeniyle ciddi nörolojik sekel bulguları gözlendi.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142-151.
  • 2. Curuk MA, Zeren F, Genc A, et al. Prenatal diagnosis of sickle cell anemia and beta-thalassemia in southern Turkey. Hemoglobin 2008;32:525-530.
  • 3. Mengnjo MK, Kamtchum-Tatuene J, Nicastro N, Noubiap JJ. Neurological complications of sickle cell disease in Africa: protocol for a systematic review. BMJ Open 2016;6:e012981.
  • 4. Alkan O, Kizilkilic E, Kizilkilic O, et al. Cranial involvement in sickle cell disease. Eur J Radiol 2010;76:151-156.
  • 5. Farooq S, Testai FD. Neurologic complications of sickle cell disease. Curr Neurol Neurosci Rep 2019;19:17.
  • 6. Ali SB, Reid M, Fraser R, MooSang M, Ali A. Seizures in the Jamaica cohort study of sickle cell disease. Br J Haematol 2010;151:265-272.
  • 7. Solh Z, Taccone MS, Marin S, Athale U, Breakey VR. Neurological PRESentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease. Pediatr Blood Cancer 2016;63:983-989.
  • 8. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood 2016;127:829-838.
  • 9. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119:4587-4896.
  • 10. DeBaun MR, Schatz J, Siegel MJ, et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 1998;50:1678-1682
  • 11. Brown RT, Davis PC, Lambert R, et al. Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease. J Pediatr Psychol 2000;25:503-513.
  • 12. Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 2001;56:1109-1111.
  • 13. Steen RG, Miles MA, Helton KJ, et al. Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. AJNR Am J Neuroradiol 2003;24:382-389.
  • 14. Steen RG, Fineberg-Buchner C, Hankins G, et al. Cognitive deficits in children with sickle cell disease. J Child Neurol 2005;20:102-107.
  • 15. Hogan AM, Pit-ten Cate IM, Vargha-Khadem F, Prengler M, Kirkham FJ. Physiological correlates of intellectual function in children with sickle cell disease: hypoxaemia, hyperaemia and brain infarction. Dev Sci 2006;9:379- 387.
  • 16. Bernaudin F, Verlhac S, Freard F, et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J Child Neurol 2000;15:333-343.
  • 17. Kral MC, Brown RT, Connelly M, et al. Radiographic predictors of neurocognitive functioning in pediatric Sickle Cell disease. J Child Neurol 2006;21:37-44.
  • 18. Schatz J, White DA, Moinuddin A, Armstrong M, DeBaun MR. Lesion burden and cognitive morbidity in children with sickle cell disease. J Child Neurol 2002;17:891-895.
  • 19. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010;303:1823-1831.
  • 20. Mackin RS, Insel P, Truran D, et al. Neuroimaging abnormalities in adults with sickle cell anemia: associations with cognition. Neurology 2014;82:835-841.
  • 21. Stotesbury H, Kirkham FJ, Kolbel M, et al. White matter integrity and processing speed in sickle cell anemia. Neurology 2018;90:e2042-e2050.
  • 22. Cichowitz C, Carroll PC, Strouse JJ, Haywood C Jr, Lanzkron S. Utility of the Montreal Cognitive Assessment as a screening test for neurocognitive dysfunction in adults with sickle cell disease. South Med J 2016;109:560- 565.
  • 23. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996;47:871-875.
  • 24. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
  • 25. Selekler K, Cangöz B, Sait U. Power of discrimination of Montreal Cognitive Assessment (MOCA) Scale in Turkish patients with mild cognitive impairement and Alzheimer’s Disease. Turk J Geriatr 2010;13:168.
  • 26. Ozdilek B, Kenangil G. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson’s disease. Clin Neuropsychol 2014;28:333-343.
  • 27. Kaya Y, Aki OE, Can UA, et al. Validation of montreal cognitive assessment and discriminant power of montreal cognitive assessment subtests in patients with mild cognitive impairment and alzheimer dementia in Turkish population. J Geriatr Psychiatry Neurol 2014;27:103-109.
  • 28. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: wellsuited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
  • 29. Kasten M, Bruggemann N, Schmidt A, Klein C. Validity of the moca and mmse in the detection of mci and dementia in parkinson disease. Neurology 2010;75:478-479.
  • 30. Videnovic A, Bernard B, Fan W, et al. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington’s disease. Mov Disord 2010;25:401-404.
  • 31. Wong A, Xiong YY, Kwan PW, et al. The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. Dement Geriatr Cogn Disord 2009;28:81-87.
  • 32. Olson RA, Chhanabhai T, McKenzie M. Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer 2008;16:1273-1278.
  • 33. Gagnon JF, Postuma RB, Joncas S, Desjardins C, Latreille V. The Montreal Cognitive Assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. Mov Disord 2010;25:936-940.
  • 34. Charest K, Tremblay A, Langlois R, Roger É, Duquette P, Rouleau I. Detecting subtle cognitive impairment in multiple sclerosis with the montreal cognitive assessment. Can J Neurol Sci 2020;47:620-626.
  • 35. Paez-Venegas N, Jordan-Estrada B, Chavarria-Avila E, et al. The montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. J Clin Rheumatol 2019;25:325-328.
  • 36. Cameron J, Worrall-Carter L, Page K, et al. Does cognitive impairment predict poor self-care in patients with heart failure? Eur J Heart Fail 2010;12:508-515.
  • 37. Alagiakrishnan K, Zhao N, Mereu L, Senior P, Senthilselvan A. Montreal cognitive assessment is superior to standardized mini-mental status exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int 2013;2013:186106.
  • 38. Colgecen E, Celikbilek A, Keskin DT. Cognitive impairment in patients with psoriasis: a cross-sectional study using the montreal cognitive assessment. Am J Clin Dermatol 2016;17:413-419.
  • 39. Andreotti C, King AA, Macy E, Compas BE, DeBaun MR. The association of cytokine levels with cognitive function in children with sickle cell disease and normal mri studies of the brain. J Child Neurol 2015;30:1349-1353.
  • 40. King AA, Strouse JJ, Rodeghier MJ, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol 2014;89:162-167.
  • 41. Ruffieux N, Njamnshi AK, Wonkam A, et al. Association between biological markers of sickle cell disease and cognitive functioning amongst Cameroonian children. Child Neuropsychol 2013;19:143-160.
  • 42. Sanger M, Jordan L, Pruthi S, et al. Cognitive deficits are associated with unemployment in adults with sickle cell anemia. J Clin Exp Neuropsychol 2016;38:661-671.
  • 43. Noubiap JJ, Mengnjo MK, Nicastro N, Kamtchum-Tatuene J. Neurologic complications of sickle cell disease in Africa: A systematic review and metaanalysis. Neurology 2017;89:1516-1524.
  • 44. Kehinde MO, Temiye EO, Danesi MA. Neurological complications of sickle cell anemia in Nigerian Africans--a case-control study. J Natl Med Assoc 2008;100:394-399.
  • 45. Niebanck AE, Pollock AN, Smith-Whitley K, et al. Headache in children with sickle cell disease: prevalence and associated factors. J Pediatr 2007;151:67-72.e1.
  • 46. Dowling MM, Noetzel MJ, Rodeghier MJ, et al. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr 2014;164:1175-1180.e1.
  • 47. Silva GS, Vicari P, Figueiredo MS, et al. Migraine-mimicking headache and sickle cell disease: a transcranial Doppler study. Cephalalgia 2006;26:678- 683.
  • 48. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-294.
  • 49. Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol 2009;84:548- 552.
  • 50. Gueguen A, Mahevas M, Nzouakou R, et al. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. Am J Hematol 2014;89:267-272.
  • 51. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 2006;118:1916- 1924.
  • 52. Oguz M, Aksungur EH, Soyupak SK, Yildirim AU. Vein of Galen and sinus thrombosis with bilateral thalamic infarcts in sickle cell anaemia: CT followup and angiographic demonstration. Neuroradiology 1994;36:155-156.
  • 53. Ciurea SO, Thulborn KR, Gowhari M. Dural venous sinus thrombosis in a patient with sickle cell disease: case report and literature review. Am J Hematol 2006;81:290-293.
  • 54. Adam SS, Flahiff CM, Kamble S, et al. Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Adv 2017;1:1983- 1992.
  • 55. Wallen GR, Minniti CP, Krumlauf M, et al. Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry 2014;14:207.
APA SIMSEK ERDEM N, Erdem R, Kurtoglu E, Oktay G (2021). Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. , 158 - 163. 10.4274/tnd.2021.89983
Chicago SIMSEK ERDEM NAZAN,Erdem Ramazan,Kurtoglu Erdal,Oktay Gönül Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. (2021): 158 - 163. 10.4274/tnd.2021.89983
MLA SIMSEK ERDEM NAZAN,Erdem Ramazan,Kurtoglu Erdal,Oktay Gönül Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. , 2021, ss.158 - 163. 10.4274/tnd.2021.89983
AMA SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. . 2021; 158 - 163. 10.4274/tnd.2021.89983
Vancouver SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. . 2021; 158 - 163. 10.4274/tnd.2021.89983
IEEE SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G "Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia." , ss.158 - 163, 2021. 10.4274/tnd.2021.89983
ISNAD SIMSEK ERDEM, NAZAN vd. "Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia". (2021), 158-163. https://doi.org/10.4274/tnd.2021.89983
APA SIMSEK ERDEM N, Erdem R, Kurtoglu E, Oktay G (2021). Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. Türk Nöroloji Dergisi, 27(2), 158 - 163. 10.4274/tnd.2021.89983
Chicago SIMSEK ERDEM NAZAN,Erdem Ramazan,Kurtoglu Erdal,Oktay Gönül Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. Türk Nöroloji Dergisi 27, no.2 (2021): 158 - 163. 10.4274/tnd.2021.89983
MLA SIMSEK ERDEM NAZAN,Erdem Ramazan,Kurtoglu Erdal,Oktay Gönül Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. Türk Nöroloji Dergisi, vol.27, no.2, 2021, ss.158 - 163. 10.4274/tnd.2021.89983
AMA SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. Türk Nöroloji Dergisi. 2021; 27(2): 158 - 163. 10.4274/tnd.2021.89983
Vancouver SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia. Türk Nöroloji Dergisi. 2021; 27(2): 158 - 163. 10.4274/tnd.2021.89983
IEEE SIMSEK ERDEM N,Erdem R,Kurtoglu E,Oktay G "Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia." Türk Nöroloji Dergisi, 27, ss.158 - 163, 2021. 10.4274/tnd.2021.89983
ISNAD SIMSEK ERDEM, NAZAN vd. "Screening of Cognitive Dysfunction Using the Montreal Cognitive Assessment Test and Evaluation of Neurologic Complications in Turkish Adults With Sickle Cell Anemia". Türk Nöroloji Dergisi 27/2 (2021), 158-163. https://doi.org/10.4274/tnd.2021.89983